Keywords
Treatment progress
Drug resistance mechanism
Endocrine therapy
Targeted therapy
Submitted : 2024-10-28
Accepted : 2024-11-12
Published : 2024-11-27
Abstract
Triple-positive breast cancer is a special type of breast cancer characterized by significant specificity in its clinical features and biological manifestations. Unlike the treatment strategies for simple hormone receptor (HR)-positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancer, triple-positive breast cancer is sensitive to endocrine therapy, adjuvant therapy, and targeted therapy. With the in-depth study of the complex drug resistance mechanisms of triple-positive breast cancer, relevant treatment options are continuously optimized, providing new directions for the treatment of this disease.
References
Wang X, Ding G, Wang H, et al., 2022, Epidemiological Characteristics and Trends of Breast Cancer in Tumor Registration Areas of Gansu Province from 2009 to 2015. China Cancer Prevention and Treatment Journal, 14(1): 99–104.
Li H, Guo C, Wang H, et al., 2022, Epidemiological Analysis of 1701 Breast Cancer Patients in a Tertiary Hospital in Urumqi, Xinjiang. Practical Oncology Journal, 37(6): 975–979.
Zhang X, Han Z, 2024, Prognostic Analysis of Triple-Positive Breast Cancer and HER-2 Overexpressed Breast Cancer. Journal of Xuzhou Medical University, 44(5): 313–318.
Wu H, Duan H, 2024, Pathological Analysis of Axillary Lymph Nodes After Neoadjuvant Chemotherapy in Patients with HER-2 Positive and Triple-Negative Breast Cancer. Journal of Xinxiang Medical College, 41(4): 358–362.
Lan H, Zhang Y, 2024, Research Progress on Endocrine Resistance Mediated by Receptor Tyrosine Kinase Signaling Pathway in Breast Cancer. Clinical Medical Research and Practice, 9(5): 190–194.
Zhang Y, Sun L, Wang Y, et al., 2017, Clinical Observation of Trastuzumab Combined with Endocrine Maintenance Therapy for HR and HER-2 Positive Advanced Breast Cancer. Journal of Clinical Oncology, 22(5): 427–431.
Zhang Y, Lu Y, Zhang H, 2021, Mechanism of Bicalutamide on Breast Cancer Cell Line MDA-MB-453 and Evaluation of its Combination with Everolimus. Cancer Research and Prevention, 48(3): 239–243.
Chen B, 2019, A New Drug for the Treatment of Advanced Breast Cancer with PIK3CA Gene Mutation—Alpelisib. Medical Bulletin, 38(11): 1528–1534.
Chen J, Xi Z, Pei X, et al., 2024, Efficacy and Safety Observation of Palbociclib, Letrozole, and Fulvestrant Combination Therapy for Advanced HR+/HER2- Breast Cancer. Modern Oncology, 32(5): 838–842.
Zhu Z, 2024, Evaluation of the Clinical Effect of Pertuzumab Combined with Trastuzumab in the Treatment of HER-2 Positive Breast Cancer. Modern Medicine and Health Research (Electronic Edition), 8(7): 81–84.